Details

Autor(en) / Beteiligte

• Shi, Yuankai
• Jia, Bo
• Xu, Wei
• Li, Wenyu
• Liu, Ting
• Liu, Peng
• Zhao, Weili
• Zhang, Huilai
• Sun, Xiuhua
• Yang, Haiyan
• Zhang, Xi
• Jin, Jie
• Jin, Zhengming
• Li, Zhiming
• Qiu, Lugui
• Dong, Mei
• Huang, Xiaobing
• Luo, Yi
• Wang, Xiaodong
• Wang, Xin
• Wu, Jianqiu
• Xu, Jingyan
• Yi, Pingyong
• Zhou, Jianfeng
• He, Hongming
• Liu, Lin
• Shen, Jianzhen
• Tang, Xiaoqiong
• Wang, Jinghua
• Yang, Jianmin
• Zeng, Qingshu
• Zhang, Zhihui
• Cai, Zhen
• Chen, Xiequn
• Ding, Kaiyang
• Hou, Ming
• Huang, Huiqiang
• Li, Xiaoling
• Liang, Rong
• Liu, Qifa
• Song, Yuqin
• Su, Hang
• Gao, Yuhuan
• Liu, Lihong
• Luo, Jianmin
• Su, Liping
• Sun, Zimin
• Tan, Huo
• Wang, Huaqing
• Wang, Jingwen
• Wang, Shuye
• Zhang, Hongyu
• Zhang, Xiaohong
• Zhou, Daobin
• Bai, Ou
• Wu, Gang
• Zhang, Liling
• Zhang, Yizhuo

Titel

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

Ist Teil von

• Journal of hematology and oncology, 2017-03, Vol.10 (1), p.69-69, Article 69

Ort / Verlag

England: BioMed Central

Erscheinungsjahr

2017

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• The efficacy and safety of chidamide, a new subtype-selective histone deacetylase (HDAC) inhibitor, have been demonstrated in a pivotal phase II clinical trial, and chidamide has been approved by the China Food and Drug Administration (CFDA) as a treatment for relapsed or refractory peripheral T cell lymphoma (PTCL). This study sought to further evaluate the real-world utilization of chidamide in 383 relapsed or refractory PTCL patients from April 2015 to February 2016 in mainland China. For patients receiving chidamide monotherapy (n = 256), the overall response rate (ORR) and disease control rate (DCR) were 39.06 and 64.45%, respectively. The ORR and DCR were 51.18 and 74.02%, respectively, for patients receiving chidamide combined with chemotherapy (n = 127). For patients receiving chidamide monotherapy and chidamide combined with chemotherapy, the median progression-free survival (PFS) was 129 (95% CI 82 to 194) days for the monotherapy group and 152 (95% CI 93 to 201) days for the combined therapy group (P = 0.3266). Most adverse events (AEs) were of grade 1 to 2. AEs of grade 3 or higher that occurred in ≥5% of patients receiving chidamide monotherapy included thrombocytopenia (10.2%) and neutropenia (6.2%). For patients receiving chidamide combined with chemotherapy, grade 3 to 4 AEs that occurred in ≥5% of patients included thrombocytopenia (18.1%), neutropenia (12.6%), anemia (7.1%), and fatigue (5.5%). This large real-world study demonstrates that chidamide has a favorable efficacy and an acceptable safety profile for refractory and relapsed PTCL patients. Chidamide combined with chemotherapy may be a new treatment choice for refractory and relapsed PTCL patients but requires further investigation.